Analyst Keeps Gilead Sciences a Buy and 3 and Stock Analyses Buzzing Now

Charles River Laboratories International, Inc. (NYSE:CRL): Sterne Agee claims that it has confirmed various times that Charles River Labs won a large GLP toxicology partnership with a large pharma company. The firm continues to be an aggressive buyer of CRL shares.

Gilead Sciences Inc. (NASDAQ:GILD): According to Deutsche Bank, its opinion regarding Gilead┬áhasn’t changed after Bristol-Myers (NYSE:BMY) and Abbott (NYSE:ABT) reported favorable results of studies of their HCV drugs. The firm believes thinks that the studies’ results indicate that utilizing different drug combinations cause more effective HCV treatments, and that this data is good news for Gilead’s 7977 based class combos. Deutsche predicts that one of Gilead’s combos will yield data similar to that of Abbott’s combo, and the firm keeps its Buy rating on the stock.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Con-way Inc. (NYSE:CNW) has been removed from Deutsche Bank’s short-term buy list because of a weaker than expected freight environment in September.

Lumber Liquidators Holdings, Inc. (NYSE:LL): The Census Bureau reported that sales at floor covering stores saw a 22.1 percent boost year-over-year during August, and Piper Jaffray thinks that this data is good news for Q3 sales trends at Lumber Liquidators. The firm believes that the company will report strong results and guidance for the remainder of 2012 and 2013, and it keeps its Overweight rating on the stock.

Don’t Miss: Cigarette Advertising Faces Extinction: What Will Big Tobacco Do?